Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Velcade Wins FDA Clearance In First-Line MM

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.

You may also be interested in...



Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment

Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.

Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment

Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.

Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share

NICE posts positive recommendation for Vidaza payment in England, Wales.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel